• Non ci sono risultati.

Ranking Overall Ranking Index 2012

N/A
N/A
Protected

Academic year: 2022

Condividi "Ranking Overall Ranking Index 2012"

Copied!
2
0
0

Testo completo

(1)

13/09/13 Ranking | Access to Medicine Index

www.accesstomedicineindex.org/ranking 1/2

Home Media FAQ Contact

Search

About the Index Index 2014 Index 2012 Companies Publications News The Foundation

Ranking Key Findings Key Trends Methodology Previous Indices Resources

Ranking

All criteria Management Public Policy R&D Pricing Patents Capability Donations

1 GlaxoSmithKline plc 3.8

2 Johnson & Johnson 3.6

3 Sanofi 3.2

4 Merck & Co. Inc. 3.1

5 Gilead Sciences 3.0

6 Novo Nordisk A/S 3.0

7 Novartis AG 2.9

8 Merck KGaA 2.5

9 Bayer AG 2.4

10 Roche Holding Ltd. 2.3

11 Pfizer Inc. 2.2

12 Bristol-Myers Squibb Co. 2.1

Overall Ranking Index 2012

The 2012 Access to Medicine Index was published on November 28

th

, 2012. The report evaluates the top 20 pharmaceutical companies' access to medicine activities.

Click on a company name to find out more about its 2012 Index performance, or use the tabs at the top to see company rankings in specific areas.

Scores

Company scores are calculated on a relative scale of 0 to 5, with 0 indicating the lowest score among the company set and 5 signifying the highest score among the company set.

Scores in this graph have been rounded to the nearest tenth

for easier reading, but unrounded scores were used in all

(2)

13/09/13 Ranking | Access to Medicine Index

www.accesstomedicineindex.org/ranking 2/2

247

13 Abbott Laboratories Inc. 2.0

14 Eli Lilly & Company 2.0

15 Eisai Co. Ltd. 1.9

16 AstraZeneca plc 1.6

17 Boehringer-Ingelheim 1.5

18 Takeda Pharmaceutical Co. 1.1

19 Daiichi Sankyo Co. Ltd. 0.9

20 Astellas Pharma Inc. 0.9

0 1 2 3 4 5

calculations.

Resources

For additional clarification and background information, please consult the Resources page.

ShareShareShare More

Publications

› 2010 Access to Medicine Index

› 2012 Methodology Report - Stakeholder Review

› Full Report 2012 Access to Medicine Index

Stay up to date

› Twitter Access to Medicine Index

› Twitter Wim Leereveld

› LinkedIn Access to Medicine Foundation

› Newsletter

› RSS

Contact

Scheepmakersdijk 5A 2011 AS Haarlem The Netherlands +31 23 533 91 87

› info@atmindex.org

© 2012 Access to Medicine Foundation. All Rights Reserved. | Disclaimer

Riferimenti

Documenti correlati

As soon as the course of treatment indicates that occupational integration measures will be necessary, Suva has the insured person registered with disability insurance in order to

Mask R-CNN (Section. 3.1), and obtain foreground masks of the objects with the bounding boxes that are ex- panded (see Section. 3.3.2) in order to include a substantial

The new third-generation Fortimo (with power up to 6000lm) has all of the comfort of the previous generations, while using an even, large-sized light source compared to single

BUSTINA RETTANGOLARE RECTANGULAR SUGAR SACHETS RECHTECKIGE ZUCKERBEUTEL. TOVAGLIETTE E BUSTE PORTAPOSATE PLACEMATS AND

Isolante per doratura naturale trasparente, da applicarsi su Fondo Zapon 2K quale corretto promotore di adesione della Missione all’acqua acrilica a dorare.. ISOLANTE ZAPON

Of those concerning aspects of the substantive discipline, the need for the arbitration clause to be included in both the deed of incorporation and in the company charter

The DuPont Oval Logo, DuPont™, The miracles of science™ and all products denoted with ® or ™ are trademarks or registered trademarks of DuPont or its affiliates. du Pont de Nemours

pH (come soluzione acquosa) Nessun informazioni disponibili Nessuna informazione disponibile Viscosità cinematica Nessun informazioni disponibili Nessuno noto.